Jun 01,2022

Prince Edward Island Becomes a National Leader in Providing Coverage for Dexcom G6 Continuous Glucose Monitoring System for Canadians With Diabetes

Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (rtCGM), announced today that people with type 1 and type 2 diabetes age two and over on multiple daily injections of insulin (three or more) or who use an insulin pump may now be eligible for public coverage of the Dexcom G6 CGM System through Prince Edward Island’s Diabetes Glucose Sensor Program.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 02,2022

Insights on the Blood Glucose Monitoring Devices Global Market to 2030 - Increasing Awareness About Diabetes Preventive Care is Driving Growth

The global blood glucose monitoring devices market size is expected to reach USD 23.15 billion by 2030. The market is expected to expand at a CAGR of 8.0% from 2022 to 2030.

View Analyst & Ambassador Comments
Go to original news
Jun 02,2022

Insulet to Present at the William Blair & Company 42nd Annual Growth Stock Conference

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the William Blair & Company 42nd Annual Growth Stock Conference in Chicago on Wednesday, June 8, 2022, at 9:00 a.m. (Eastern Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 02,2022

Diabeloop announces 70 million euros new financing round to accelerate its international expansion

Diabeloop closes its Series C financing round - led by LBO France, joined by Terumo Corporation, Innovacom and backed by Diabeloop’s historical partners - to power the company’s commercial roll-out and global expansion.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Jun 02,2022

Dexcom to Showcase Expanded CGM Portfolio and Industry-leading Connectivity at 82nd Scientific Sessions of the American Diabetes Association

DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, will showcase its expanded global portfolio of real-time continuous glucose monitoring (CGM) systems at the 82nd Scientific Sessions of the American Diabetes Association (ADA) conference held in New Orleans and virtually, June 3-7, 2022.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 02,2022

BD to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Goldman Sachs 43rd Annual Global Healthcare Conference on Thursday, June 16, 2022 at 11:00 a.m. Eastern Time.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 02,2022

Insights on the Glucose Biosensors Global Market to 2030 - Rising Demand for Minimally and Small-Sized Glucose Monitoring Devices is Driving Growth

The global glucose biosensor market size is expected to reach USD 20.1 billion by 2030. The market is expected to expand at a CAGR of 7.9% from 2022 to 2030.

View Analyst & Ambassador Comments
Go to original news
Jun 03,2022

ABBOTT ANNOUNCES DEVELOPMENT OF NOVEL CONTINUOUS GLUCOSE-KETONE MONITORING SYSTEM

Abbott (NYSE: ABT) today announced it's developing a new biowearable that will continuously monitor glucose and ketone levels in one sensor. The system has secured breakthrough device designation from the U.S. Food and Drug Administration, which is designed to expedite the review of innovative technologies that can improve the lives of people with life-threatening or irreversibly debilitating diseases or conditions.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 03,2022

DarioHealth Presents Three New Studies Demonstrating Improved Health in Users with Multiple Conditions at the American Diabetes Association's 82nd Scientific Sessions

Two of the new studies add to Dario's growing body of evidence in support of an integrated approach to managing multiple chronic conditions by examining the impact of Dario's solution on users with co-occurring physical and mental conditions. The third study analyzed the impact across the ethnicities of users living with Type 2 diabetes.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jun 03,2022

Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years

Omnipod 5, the first tubeless, wearable automated insulin delivery (AID) system in the U.S., significantly improved time in range and reduced HbA1c in children aged 2 through 5.9 years with type 1 diabetes over 12 months of use.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES